Discounted Drugs for Clinical Trials Act

Senate Bill 4026 - Discounted Drugs for Clinical Trials Act: Overview, Status, and Impact

Hozzl · 2022-12-29T23:48:38Z

Explore the details of Senate Bill 4026 Discounted Drugs for Clinical Trials Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 11:48 PM

Congressional Summary of S 4026

Discounted Drugs for Clinical Trials Act

This bill allows researchers to obtain certain high-cost drugs and biologics at discounted prices from manufacturers. Researchers must apply to the Food and Drug Administration for approval; manufacturers must sell the approved quantity of drugs to researchers at the discounted price and are subject to civil actions from researchers for noncompliance.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 4026

Bill S 4026 is currently in the status of Bill Introduced since April 7, 2022. Bill S 4026 was introduced during Congress 117 and was introduced to the Senate on April 7, 2022. Bill S 4026's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of April 7, 2022

Bipartisan Support of Bill S 4026

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 4026

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4026

Discounted Drugs for Clinical Trials Act

A bill to amend the Federal Food, Drug, and Cosmetic Act to grant eligible researchers access to eligible products at a discounted price for qualified research, and for other purposes.